In the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial using either 80 mg of atorvastatin or 40 mg of pravastatin, the correlation between the achieved values was small, so that less than 3% of the variance in followed-up CRP levels was explained by the variance in achieved LDL-C levels [24]. Here, CRP is linked to infection.